As with all solutions available from Nobel Biocare, the creos family of products is clinically proven to be safe and effective.

The creos xenoprotect resorbable, non-cross-linked collagen membrane has been shown to produce an 81% reduction in defect height six months following the augmentation procedure, compared to a 62% reduction with Bio-Gide (Geistlich). There was also a trend toward lower membrane exposure rates with creos xenoprotect compared to Bio-Gide.

The creos xenogain bone substitute is the newest product in the portfolio, providing a slow resorption rate and a long-lasting scaffold that maintains space for successful bone regeneration. With a calcium phosphate ratio that reflects the composition of human bone and a low crystalline structure, the biocompatible creos xenogain is also readily accepted by the body as a suitable framework for successful bone formation.

To find out more about the clinically proven creos family of products from Nobel Biocare and to discover how it could help your implant patients, contact the team today on 0208 756 3300, or visit the Nobel Biocare website: www.nobelbiocare.com.